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Abstract
Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with signiﬁcant morbidity and mortality.
These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the pre-
vention of IC in neonates at high risk include ﬂuconazole (A-I), nystatin (B-II) or lactoferrin ± Lactobacillus (B-II). The treatment of IC in neo-
nates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system.
Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), ﬂuconazole (B-II), micafun-
gin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated
from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, ﬂuconazole
(A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for
the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are
extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B
(A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), ﬂuconazole (B-I) and voriconazole (B-I) can all be used.
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Introduction
The process of deﬁning therapeutic recommendations in this
document is consistent with paediatric development regula-
tions and guidelines from the European Medicines Agency
(EMA) [1,2]. The EMA has a relatively pragmatic approach to
the licensure of pharmaceutical agents for neonates and chil-
dren. The EMA accepts the requirement for extrapolation of
evidence for efﬁcacy from studies in adults to paediatric
patients, or from older to younger paediatric patients when
the following criteria are met: (i) a medicinal product is to
be used for the same indication(s); (ii) the disease process or
target sensitivity is similar; and (iii) the outcome of therapy is
likely to be comparable [1,2].
Pharmacokinetic studies performed in all the age ranges of
paediatric patients likely to receive a compound, together
with safety studies, may provide adequate information for
use by allowing selection of paediatric doses that will pro-
duce drug exposure similar to those observed in adults. In
situations where the comparability of the disease course or
outcome of therapy is expected to be similar, but the rele-
vant drug exposure in adults is not known, a pharmacokinet-
ics/pharmacodynamics approach combined with safety and
other relevant studies may avoid the need for clinical efﬁcacy
studies [1]. More complex disease–drug combinations may
require speciﬁc studies.
The grading scheme used in this manuscript is consistent
with guidelines developed for adults [141]. However, there
are some subtle differences for paediatric patients. The
Expert Group considered three components for grading of
each drug–syndrome combination: (i) evidence for efﬁcacy,
which was frequently, but not invariably, obtained from
studies in adults; (ii) the quality of the pharmacokinetic data
and models performed in either neonates or children that
enable an informed decision about an appropriate regimen
for the speciﬁc population; and (iii) speciﬁc safety data
obtained in neonates or children that support the use of a
given compound in that speciﬁc population. These guidelines
are intended to facilitate optimal antifungal therapy for neo-
nates and children with invasive candidiasis. They are not
necessarily exhaustive. Contraindications, drug–drug interac-
tions and speciﬁc warnings for each compound should be
considered by treating physicians. Furthermore, these guide-
lines should be coupled with diagnostic and therapeutic
algorithms tailored to the speciﬁc case mix and local fungal
epidemiology of each institution. The incorporation of these
therapeutic guidelines with a risk stratiﬁcation strategy is
also recommended, especially for prophylaxis and empirical
antifungal therapy.
Overview of syndromes and pathogenesis
of invasive candidiasis in paediatrics
Neonates
Invasive candidiasis (IC) is a common and serious infection in
premature neonates [3]. Invasive candidiasis may present as can-
didaemia, urinary tract infection and involvement of essentially
any other tissue or structure. A syndrome that is particularly
unique to premature infants is haematogenous Candida menin-
goencephalitis (HCME), where there is invasion of the central
nervous system (CNS) by Candida. This syndrome occurs in 15–
20% of cases of IC and may contribute to the increased mortal-
ity and long-term neurodevelopmental abnormalities [3,4].
The risk factors for development of IC in the neonatal
intensive care unit (NICU) include prematurity, central vas-
cular catheterization, abdominal surgery, necrotising entero-
colitis (NEC), exposure to broad-spectrum antibacterial
agents (e.g. third-generation cephalosporins and carbapen-
ems), parenteral nutrition, antacids and endotracheal intuba-
tion. Infants with a smaller gestational age have a higher
incidence of IC (e.g. neonates with gestational age of 23–24,
25–27 and ‡28 weeks have an incidence of 10–20%, 5–10%
and <5%, respectively [5]). Similarly, smaller infants have a
higher incidence of IC (e.g. neonates with birth weight
<750 g, 750–1000 g and >1000 g have an incidence of IC of
>10%, 5–10% and <5%, respectively).
Candida albicans is the most frequent Candida species caus-
ing IC in neonates [6,7]. Candida parapsilosis, Candida tropicalis
and other Candida species are seen less commonly. Unlike
adults, Candida glabrata and Candida krusei are infrequent
causes of IC in the NICU.
Older children
The invasive Candida syndromes in older children closely
resemble those seen in adults. Candida spp. are important
causes of healthcare–associated infections in children and
adolescents with indwelling central venous catheters, in pae-
diatric cancer patients receiving treatment for haematological
malignancies and in paediatric haematopoitic stem cell trans-
plant (HSCT) recipients. Severe sepsis and/or septic shock
occurs in approximately 30% [8,9]; mortality rates range
between 10 and 25% in most series [9] and are close to 50%
in patients admitted to the ICU [8,10,11]. IC is also an
important syndrome in solid organ transplant recipients. The
incidence in this setting remains relatively poorly deﬁned, but
is c. 5–10% in liver, small bowel and pancreas transplantation
[12]. In the individual reports that are available, the incidence
of IC for paediatric heart, lung and liver transplant recipients
is 3.9%, 5% and 19%, respectively [10,13,14].
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Prevention of IC in neonates (see Table 1)
General principles
Antifungal prophylaxis may be an appropriate strategy, espe-
cially for the most vulnerable patients (e.g. extremely low-
birth-weight [ELBW] neonates [i.e. <1000 g]). Avoidance of
horizontal transmission in the NICU is paramount and
requires rigorous infection control measures [15]. Treatment
of maternal vaginal candidiasis prior to delivery may prevent
subsequent neonatal colonization [15]. Rational use of
broad-spectrum antibacterial agents (especially third-genera-
tion cephalosporins and carbapenems) and central venous
catheters is probably important, although there is no speciﬁc
evidence to support these interventions. The Expert Group
has evaluated three prophylactic strategies for IC in prema-
ture neonates: (i) oral nonabsorbable antifungal agents; (ii)
oral administration of Lactobacillus and lactoferrin; and (iii) i.v.
and oral administration of ﬂuconazole.
Nonabsorbable antifungal agents
Nonabsorbable antifungal agents are used to decrease the
burden of Candida in the gut and therefore the probability of
translocation into the bloodstream. Currently available
agents include nystatin (1 mL suspension, 100 000 U/mL,
every 8 h, during high-risk period) and miconazole oral gel
15 mg Q8 h.
There is a reasonable amount of data that support the use
of nystatin for neonates <1500 g (B-II). This recommendation
is based on randomized controlled trials that have compared
the utility of oral nystatin versus no medication for the pre-
vention of IC [16,17]. A subsequent Cochrane review and
meta-analysis suggest that oral nystatin results in a signiﬁcant
reduction in IC, but has no impact on mortality [18]. Two
further studies have compared nystatin with ﬂuconazole
[19,20]. While the impact of nystatin on IC is variable (some
studies [16,17,19] suggest that the use of nonabsorbable
agents results in a reduction in colonization and IC [e.g. from
c. 44 to 12% and c. 4–32 to 1.8–6%, respectively, while oth-
ers do not [20]]), there is no impact on mortality, and
longer-term outcomes have not been assessed. A potential
problem with the use of nonabsorbable agents is inadvertent
damage of the very fragile gut epithelium of premature
infants and the subsequent development of necrotizing
enterocolitis (NEC). A grading of B-II reﬂects the potential
concern for the development of NEC, the absence of an
overall effect on mortality and methodological weaknesses in
these studies.
Miconazole is an alternative nonabsorbable agent for
the prevention of IC in neonates. The only trial that has
examined the utility of miconazole for this indication in neo-
nates suggests that there is a reduction in rectal colonization
by Candida, but no impact upon IC [21]. Given the potential
for the development of triazole resistance that may preclude
the subsequent use of ﬂuconazole, the Expert Group sug-
gests a grading of D-II.
Administration of Lactobacillus and lactoferrin
The administration of Lactobacillus casei subsp. rhamnosus is
intended to prevent the establishment of a microbiological
niche for Candida spp. in the gut. Studies of oral probiotic
administered (106 colony-forming units per day) from the
third day of life until either the end of the sixth week of life
or until discharge from the NICU suggest that this approach
prevents enteric colonization by Candida species, but has no
impact on the overall incidence of IC [22]. Lactoferrin is an
alternative agent that may be effective via the abrogation of
the invasive potential of Candida spp. The administration of
bovine lactoferrin (100 mg/day), alone or in combination
with Lactobacillus rhamnosus GG, signiﬁcantly reduces the
incidence of late-onset sepsis in very low-birth-weight
(VLBW, <1500 g) neonates, including those episodes attrib-
utable to Candida [23]. Bovine lactoferrin does not affect the
incidence of Candida colonization but reduces the incidence
of IC in VLBW neonates [24]. The Expert Group considers
that lactoferrin alone or in combination with Lactobacillus is
equally reasonable (B-II).
Fluconazole prophylaxis
The use of ﬂuconazole (i.v. or oral) is supported by robust
data that attest to both the efﬁcacy and safety of this agent.
Five RCTs [19,25–28], eight historical control studies [29–
36] and one meta-analysis [37] have examined the utility of
ﬂuconazole for the prevention of IC in neonates. Collec-
tively, all these studies suggest that prophylactic administra-
tion of ﬂuconazole 3–6 mg/kg/dose (i.v. or oral) twice
weekly results in a reduction in Candida colonization and a
91% decrease of IC in neonates <1000 g. While there is a
reduction in mortality, this is not statistically signiﬁcant (RR
0.74 [CI 0.51–1.09]) [37,38]. Potential theoretical concerns
with the routine use of ﬂuconazole include neurodevelop-
mental toxicity and emergence of drug resistance. Reassur-
ingly, a recent study suggests no toxicity after 8–10 years,
nor the emergence of less susceptible or inherently resistant
Candida species in the NICU [39]. Of note, studies examining
ﬂuconazole prophylaxis were conducted in NICUs with rela-
tively high incidence of IC (e.g. >12%). Most NICUs have an
incidence of IC of <5% for neonates <1000 g, and some <2%
[40]. The potential beneﬁts of ﬂuconazole prophylaxis may
be less with a low incidence of IC.
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The Expert Group recommends that the use of ﬂuconaz-
ole is combined with a risk stratiﬁcation strategy. Thus,
ﬂuconazole 3–6 mg/kg/dose twice weekly i.v. or orally is
appropriate for all neonates <1000 g in NICUs with rela-
tively high frequency of IC (A-I). For NICUs with a lower
incidence of IC (i.e. <2%), the decision to use the same
ﬂuconazole prophylaxis regimen should be made on a case-
by-case basis and embedded in a risk stratiﬁcation strategy
(e.g. <1000 g, additional risk factors for IC such as central
venous catheterization, receipt of third-generation cephalo-
sporins or carbapenems) (B-II).
Treatment of IC in neonates (See Table 2)
General principles
Because cultures from deep sites are frequently negative, a
deﬁnitive diagnosis of IC in neonates may be problematic [3].
Information on local epidemiology may help guide initial ther-
apy [6]. Any premature infant with microbiological or clinical
evidence of invasive candidiasis should be assumed to have
disseminated disease, and this should prompt a thorough
clinical examination and relevant investigations. In particular,
the possibility of HCME should be considered, and if deemed
probable, antifungal therapy should be designed to treat the
CNS [41]. This important pharmacodynamic difference
between neonates and adults means that the strategy of
combining efﬁcacy data from adults with well-designed PK
studies in neonates may not be appropriate. In this regard,
the Expert Group notes that evidence to support various
compounds in neonatal settings is accrued either from: (i)
case series describing the outcome of drug therapy in neo-
nates or (ii) in vivo to clinical bridging studies. The latter has
been recently applied to the echinocandins.
Amphotericin B formulations
Amphotericin B deoxycholate 1 mg/kg/day can be used for
the treatment of IC in neonates (B-II). This recommendation
is supported by relatively limited clinical data for IC [42] and
HCME [43]. The recommendation is also supported by lim-
ited pharmacokinetic data [44]. There is no speciﬁc clinical
information for optimal regimen for the treatment of HCME,
although amphotericin B deoxycholate is effective in a pre-
clinical model of HCME [45]. Liposomal amphotericin B 2.5–
7 mg/kg/day can be used for IC in neonates [46–48] (B-II)
and is safe [49]. While there is no speciﬁc clinical informa-
tion for the optimal regimen for HCME, liposomal amphoter-
icin B penetrates the CNS in a preclinical model of HCME
and has antifungal activity in the brain [45]. ABLC 2.5–5 mg/
kg/day i.v. is an alternative agent to both LAmB and DAmB
(C-II). Evidence for efﬁcacy and the population pharmacoki-
netics of ABLC have been described in neonates [50]. Fur-
thermore, preclinical data suggest ABLC is effective for
HCME [45]. The lower grading compared with other ampho-
tericin B formulations reﬂects continuing uncertainty regard-
ing the use of this agent for IC in general (for both children
and adults) and the relative paucity of clinical data compared
with other formulations.
Triazoles
There are relatively few studies that have speciﬁcally exam-
ined the efﬁcacy of ﬂuconazole for neonates. Fluconazole (12
mg/kg with consideration given to a loading dose of 25 mg/kg
although further safety studies are required) can be used to
treat IC in neonates who have not previously received this
agent (B-II). This recommendation is based on data for efﬁ-
cacy and safety in neonates [51–53]. Recent population phar-
macokinetic studies have been used to deﬁne an appropriate
regimen [54,55]. There are no preclinical or clinical data that
are available to guide deﬁnitive regimens for HCME. Potential
limitations of ﬂuconazole include a relatively narrow spectrum
of antifungal activity compared with other antifungal agents,
and a fungistatic (as opposed to fungicidal) antifungal effect.
Echinocandins
The echinocandins are increasingly used for treatment of IC
in the NICU. The recommendation for micafungin 4–10 mg/
kg/day (B-II) is based on a PK–PD bridging study and detailed
PK studies [56–58]. Micafungin 4 mg/kg approximates drug
exposures achieved in adults. If HCME is thought to be
likely, a higher dosage (e.g. 10 mg/kg) should be used
because of the dose-dependent penetration of micafungin
into the CNS [57]. The Expert Group notes the ‘black box’
warning for micafungin issued by the EMA indicating micafun-
gin should only be used if other agents are not appropriate.
This warning is based upon an increased incidence of hepatic
tumours in rats receiving prolonged dosing of micafungin. To
date, there is no corresponding clinical signal, despite exten-
sive clinical use of micafungin throughout the world. Further-
more, similar studies have not been performed for the other
echinocandins, raising uncertainty as to whether this preclini-
cal ﬁnding is a class effect. Preclinical data and PK–PD bridg-
ing studies suggest that an elevated dosage of anidulafungin
may be required to treat HCME [59]. While limited PK is
available [60], further clinical PK studies are required, and
until results from these studies are available, the Expert
Group has not graded anidulafungin for use in this setting.
The currently recommended infant dosage of caspofungin
(25 mg/m2/day) is based on achieving comparable AUCs to
those seen in adults [61]. While clinical efﬁcacy has been
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demonstrated in a small number of case reports and case
series [62–64], there is no evidence that this dosage is nec-
essarily adequate to treat infants with HCME. Moreover, the
use of body surface area as a metric of size may be inaccu-
rate in neonates. For these reasons, and until further data
are available, the Expert Group suggests a grading of C-II is
appropriate.
Prevention and treatment of invasive
candidiasis in children (See Table 3 and 4)
General principles
Primary prophylaxis is a widely accepted strategy for patients
at high risk of developing IC. The underlying incidence of IC
is the most important factor for determining whether pro-
phylaxis is a reasonable strategy, with 10% frequently being
used as a value where the risk–beneﬁt analysis is favourable.
The incidence for patients with acute myeloid leukaemia,
recurrent leukaemia and following allogeneic HSCT is 5–15%
[65–68]. For patients with acute lymphoblastic leukaemia and
solid tumours who are receiving dose-intense chemotherapy
with or without autologous stem cell rescue, the reported
incidence rates are <5% [68,69]. Apart from these general
considerations, the institutional epidemiology is the most
important consideration for designing an appropriate prophy-
lactic regimen.
Prevention of invasive candidiasis in allogeneic HSCT
recipients
Fluconazole (8–12 mg/kg QD i.v. or orally; studied from day
0 to day +75) may be used in allogeneic HSCT recipients (A-
I). This recommendation is based on randomized clinical tri-
als performed in adults who have demonstrated a reduction
in invasive Candida infections [70,71], a persistent survival
beneﬁt in one study [71,72], the existence of paediatric PK
and safety data [73–75], and a paediatric label from the EMA.
Fluconazole should only be used when the risk of invasive
mould infections is suitably low or in combination with a
screening programme for these pathogens.
Itraconazole suspension (2.5 mg/kg Q12h; started after
completion of the conditioning regimen; not approved by
the EMA in patients <18 years of age), which has additional
activity against Aspergillus spp., may also be used for children
‡2 years of age (B-II). The evidence for the use of this
agent for HSCT recipients is derived from randomized clini-
cal trials in adults [76,77] and relatively small paediatric
pharmacokinetic studies [78–80]; the latter is the reason
for the designation of level II evidence. TDM should be per-
formed to verify absorption, compliance and the attainment
of effective and nontoxic concentrations. A trough concen-
tration target of 0.5 mg/L when estimated using HPLC is
reasonable [81,82]. A further option for children aged
‡2 years is voriconazole (day 1: 9mg/kg Q12 h, then 8 mg/
kg Q12h i.v): 9 mg/kg Q12 h PO (max. 350 mg Q12 h) for
2–12 years and 12–14 years with <50 kg; adult dose for
patients 12–14 years >50 kg and for patients >14 years;
studied from day 0 until at least day +100) (A-I). The basis
for this recommendation includes a randomized clinical trial
performed in adults that demonstrates comparable prophy-
lactic efﬁcacy to ﬂuconazole [83] and adequate PK and
safety data [84–89]. An additional consideration is activity
against Aspergillus spp. Prophylactic use of voriconazole
should be coupled with therapeutic drug monitoring; a
trough concentration of ‡1 mg/L is probably a reasonable
target [89–91]. For adults with GVHD and augmented
immunosuppression, posaconazole (200 mg Q8 h) has been
shown to prevent invasive fungal infections, although there
was no effect on overall mortality [92]. Limited data in chil-
dren 13–17 years of age suggest minimal differences in
pharmacokinetics compared with adults [93]. Therefore, po-
saconazole may be appropriate for children who are receiv-
ing immunosuppression for GVHD (B-II). The Expert Group
suggests a lower recommendation than adults because of
relatively rudimentary pharmacokinetic studies in paediatric
patients. If posaconazole is used, therapeutic drug monitor-
ing should be considered, and a trough concentration of
0.7 mg/L after 1-week therapy is a reasonable therapeutic
target [94,95].
Micafungin (1 mg/kg/day i.v. administered from the begin-
ning of the preparative regimen to day +30) may be used
(A-I). This recommendation is based upon robust paediatric
PK [96,97], safety [98], regulatory approval for this indication
and a large randomized clinical trial with inclusion of paediat-
ric patients [99].
Prevention of invasive candidiasis in children with AML and
recurrent leukaemia
The recommendations for patients with AML and/or recur-
rent leukaemia are similar to the allogeneic HSCT setting;
the risk of developing invasive mould disease may be
signiﬁcant and should be considered [69]. Fluconazole (8–
12 mg/kg/day i.v./orally (max. 400 mg) after the last dose of
chemotherapy and until neutrophil recovery) [100] (A-I)
should only be used when the risk of invasive mould infec-
tions is suitably low or in combination with a screening
programme for these pathogens. Micafungin (1 mg/kg/day
i.v.) is approved for prophylaxis of invasive Candida infec-
tions in patients with profound and prolonged neutropaenia
[ANC <500 for ‡10 days]) [99](A-II). The Expert Group
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suggests level II evidence is appropriate because of the
absence of speciﬁc studies in this patient population. Posa-
conazole prevents invasive fungal infections and provides a
survival advantage for patients with AML/MDS compared
with patients receiving ﬂuconazole or itraconazole [101].
Based on limited PK and safety data [93,102], posaconazole
(200 mg Q8 h following completion of chemotherapy until
neutrophil recovery; plus TDM) (B-II) is an option for ado-
lescents >12 years of age.
Further alternatives include the following: (i) itraconazole
(2.5 mg/kg Q12h following chemotherapy with concomitant
TDM; not approved by the EMA for patients <18 years of
age) [103] (B-II); (ii) liposomal amphotericin B (1 mg/kg/every
other day) (B-I) based on studies in adult patients with leu-
kaemia [104] and concomitant paediatric pharmacokinetic
and safety data [105,106]; and (iii) voriconazole (day 1: 9 mg/
kg Q12 h, then 8 mg/kg BID i.v.); 9 mg/kg Q12 h PO (max.:
350 mg Q12 h) for 2–14 years; adult dose for patients
>14 years; plus TDM) [83,107] (A-II). Of note, both micafun-
gin and liposomal amphotericin B may be useful for patients
with acute lymphoblastic leukaemia (ALL) who are receiving
repeat treatments with vincristine and in whom antifungal
triazoles are contraindicated [108].
Prevention of invasive candidiasis in autologous HSCT
recipients and in children with ALL
Patients who have received high-dose chemotherapy with
autologous stem cell rescue (autologous HSCT), who also
have profound and prolonged neutropaenia (ANC <500 for
‡10 days) despite hematopoietic growth factors and/or
severe mucositis, may beneﬁt from primary antifungal pro-
phylaxis [100]. Because the risk of developing invasive mould
TABLE 1. Prevention of invasive candidiasis in neonates
Recommendation and grading Comments References
Oral nystatin, 1 mL 100 000 IU Q8 h (B-II) Reduction in fungal infection, but no change in mortality, potential
gut damage & NEC
[18–20]
Miconazole oral gel 15 mg Q8 h (D-II) Concerns regarding generation of triazole resistance [21]
Lactoferrin 100 mg/day alone or in combination with Lactobacillus
106 colony-forming units per day from the third day of life until
either the end of the sixth week of life or until discharge from
the NICU (B-II)
Reduction in fungal infection by Lactobacillus and lactoferrin [22–24]
Fluconazole 3 or 6 mg/kg 2 times per week iv or orally in ALL
neonates <1000 g in NICUs with high frequency of IC (A-I)
Reduction in Candida colonization, fungal infection, but no change
in overall mortality. Concerns for neurodevelopmental toxicity,
emergence of resistant species
[19,25–37,39]
Fluconazole 3 or 6 mg/kg 2 times per week iv or orally in NICUs
with a lower incidence of IC (i.e. <2%) for neonates:
(a) with birth weight <1000 g,
(b) who have risk factors (i.e. central venous catheters,
third-generation cephalosporins and carbapenems) for the
development of IC (B-II)
Decision for prophylaxis is on an individual basis References as
immediately above
TABLE 2. Therapeutic options for infants with invasive candidiasis and/or HCME
Recommendation and Grading Comments References
Amphotericin B deoxycholate 1 mg/kg/day (B-II) PK in neonates relatively poorly deﬁned, leading to
some uncertainty regarding optimal dosage for
HCME
Clinical trials in adults [123,124]
Pharmacokinetics in neonates [44]
Evidence for efﬁcacy and toxicity [43,135]
Liposomal amphotericin B 2.5–7 mg/kg/day (B-II) PK in neonates remains undeﬁned, leading to some
uncertainty regarding optimal dosage for neonates
The optimal dosage for HCME is not known
Pharmacokinetics in neonates: nil
Evidence for efﬁcacy in neonates [46–48]
Fluconazole
12 mg/kg/day, with consideration given to a loading
dose of 25 mg/kg (B-II)
Relatively limited data for the treatment of IC Evidence for efﬁcacy [51–53]
Pharmacokinetics in neonates: [54,55]
Micafungin 4–10 mg/kg/day i.v. (B-II) The EMA has issued a ‘black box’ warning on the
basis of an elevated incidence of hepatic tumours in
rats receiving prolonged dosing and drug exposures
higher than typically seen in clinical contexts. These
studies have not been performed for other
echinocandins
The currently licensed dosage is 2–4 mg/kg/day. If
HCME is present, preclinical models and PK-PD
bridging studies suggest a higher dosage is required
for effective therapy
Evidence for efﬁcacy derived from preclinical models
[57]
Pharmacokinetics in neonates: [56,58]
Caspofungin
25 mg/m2/day (C-II)
Relatively limited PK and dosing designed to
approximate drug exposure in adults, rather than
HCME
Evidence for efﬁcacy [62–64]
Pharmacokinetics in neonates: [61]
ABLC 2.5–5 mg/kg/day (C-II) The Expert Group rated ABLC ‘C’ because of the
relative paucity of clinical data
The optimal regimen for the treatment of HCME is
not known
Pharmacokinetics in neonates [50]
Preclinical data suggests that ABLC is an effective
agent for the treatment of HCME [45]
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infections is <5% [108], primary options include micafungin
(1 mg/kg QD; studied from the start of high-dose chemo-
therapy until engraftment) [99] (A-I) and ﬂuconazole (8–
12 mg/kg/day i.v./orally (max. 400 mg) (A-I) [100]. Alternative
options include itraconazole (2.5 mg/kg Q12h with TDM; not
approved in subjects <18 years of age) [103] (B-II) and
liposomal amphotericin B 1 mg/kg/every other day i.v. (B-I)
based on data derived from adult patients leukaemia [104].
TABLE 3. Primary prophylaxis of invasive candidiasis in children
Clinical Context Recommendation and Grading Comments References
Allogeneic HSCT Fluconazole 8–12 mg/kg QD i.v. or orally;
studied from day 0 until day +75
post transplant (A-I)
Fluconazole should only be used if the
institutional incidence of invasive mould
infections is low, or if there are active
diagnostic and therapeutic algorithms for mould
infections
Clinical trials in adults [70–72]
PK studies in children [73]
Safety and efﬁcacy in children [74,75]
Allogeneic HSCT Micafungin 1 mg/kg QD i.v.; studied from
the start of the preparative regimen until
day +30 (A-I)
Spectrum of antifungal activity also extends to
Aspergillus spp.
Clinical trials in adults with inclusion of
paediatric patients [99]
PK studies in children: [96,97]
Safety and efﬁcacy in children [98]
Allogeneic HSCT Voriconazole 8 mg/kg BID (day 1: 9 mg/kg
BID) for i.v., and 9 mg/kg BID for oral
administration (max.: 350 mg BID) for the
ages of 2–14 years and the approved adult
dose for patients 15 years and older and
12-14 year olds weighing >50 kg; studied
from day 0 until at least day +100 (A-I)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
TDM should be performed; dosing target/ trough
concentration of ‡1 mg/L
Clinical trials in adults [83]
PK studies in children: [84–88]
TDM dosing target: [89–91]
Safety/efﬁcacy in children: [84–89,136–138]
Allogeneic HSCT Itraconazole suspension 2.5 mg/kg Q12 h
for patients ‡2 years of age; to be started
after completion of the conditioning
regimen; studied until at least day +100
(B-II)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Not approved in patients <18 years
TDM is suggested; dosing target: trough
concentration of ‡0.5 mg/L
Clinical trials in adults: [76,77]
PK studies in children [78–80]
TDM dosing target [81,82]
Safety/efﬁcacy in children [79]
Allogeneic HSCT Posaconazole suspension 200 mg Q8 h
orally for patients with ‡ grade II GVHD
and ‡13 years of age (B-II)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Not approved in patients <18 years
TDM is suggested; dosing target: trough
concentration of ‡0.7 mg/L
Clinical trials in adults: [92]
PK studies in children: [93]
TDM dosing target [94]
Safety/efﬁcacy in children: nil
AML and recurrent
leukaemia
Fluconazole 8–12 mg/kg i.v. or orally after
last dose of chemotherapy until neutrophil
recovery (A-I)
Fluconazole should only be used if the
institutional incidence of invasive mould
infections is low, or with an active diagnostic
and therapeutic algorithms for clinical signs and
symptoms suggestive of these infections
Clinical trials in adults [100]
PK studies in children [73]
Safety/efﬁcacy in children: [74,75]
AML and recurrent
leukaemia
Micafungin 1 mg/kg QD i.v.; after last dose
of chemotherapy until neutrophil recovery
(A-II)
Prophylactic efﬁcacy inferred from study in
HSCT patients
Alternative for patients with leukaemia receiving
vincristine
As above
AML and recurrent
leukaemia
Itraconazole suspension 2.5 mg/kg Q12 h
for patients ‡2 years of age; after last dose
of chemotherapy until neutrophil recovery
(B-II)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Not approved in patients <18 years
TDM is suggested; dosing target: trough
concentration of ‡ 0.5 mg/L
Clinical trials in adults [103]
PK studies in children: [78–80]
TDM dosing target: [81,82]
Safety/efﬁcacy in children [79]
AML and recurrent
leukaemia
Liposomal amphotericin B 1 mg/kg QOD i.v.
(B-I)
Spectrum extends to Aspergillus spp. and other
medically important opportunistic moulds
Alternative antifungal agent for patients with
leukaemia receiving vincristine
Clinical trials in adults [104]
PK studies in children [105]
Safety/efﬁcacy in children [106]
AML and recurrent
leukaemia
Voriconazole 8 mg/kg BID (day 1: 9 mg/kg
BID) for i.v., and 9 mg/kg BID for oral
administration (max.: 350 mg BID) for the
ages of 2–14 years and the approved adult
dose for patients 15 years and older and
12-14 year olds weighing >50 kg; after last
dose of chemotherapy until neutrophil
recovery (B-I)
As above As above
AML and recurrent
leukaemia
Posaconazole 200 mg TID orally for patients
‡13 years of age; after last dose of
chemotherapy until neutrophil recovery
(B-II)
As above As above
Autologous HSCT Fluconazole 8–12 mg/kg i.v. or orally after
last dose of chemotherapy until neutrophil
recovery (A-I)
Patients with expected profound and prolonged
neutropaenia (ANC <500 ‡ 10 days) despite
use of growth factors and/or severe mucositis
may beneﬁt from antifungal prophylaxis
References as above
Autologous HSCT Micafungin 1 mg/kg QD i.v.; after last dose
of chemotherapy until neutrophil recovery
(A-I)
As above References as above
Autologous HSCT Itraconazole suspension 2.5 mg/kg Q12 h
for patients ‡2 years of age; after last dose
of chemotherapy until neutrophil recovery
(B-II)
As above References as above
Autologous HSCT Liposomal amphotericin B 1 mg/kg QOD i.v.
(B-I)
As above References as above
HSCT, haematopoietic stem cell transplantation; PK, pharmacokinetics; TDM, therapeutic drug monitoring.
Note that individual ALL patients exhibiting prolonged and profound neutropaenia (ANC <500 for ‡10 days) and receiving high doses of glucocorticosteroids may beneﬁt
from antifungal prophylaxis [68]. As these risk factors are shared by opportunistic moulds, a mould active agent is preferred (CIII).
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While no general recommendation can be made for de
novo acute lymphoblastic leukaemia, individual patients
exhibiting prolonged and profound neutropaenia (ANC <500
for ‡10 days) and receiving high doses of corticosteroids
may beneﬁt from antifungal prophylaxis [68]; because these
risk factors are shared by opportunistic moulds, a mould
active agent is preferred (CIII).
Prevention of invasive candidiasis in solid organ transplant
recipients and critically Ill nonneutropaenic children
Because robust data on epidemiology and risk factors are
absent, ﬁrm recommendations for the prevention of IC are
somewhat difﬁcult. The most appropriate agent depends on
the underlying incidence of invasive aspergillosis, which in
turn is a function of the transplant type and institutional inci-
dence of mould infections. If the incidence of invasive asper-
gillosis is suitably low, then ﬂuconazole 8–12 mg/kg/day i.v.
or orally is reasonable in the majority of cases (recommen-
dation not rated).
Similar uncertainties exist for critically ill nonneutropaenic
children in the paediatric intensive care unit (PICU). While no
evidence-based recommendations can be made, ﬂuconazole 8–
12 mg/kg/day i.v. or orally is a reasonable option for the pre-
vention of invasive candidiasis in critically ill nonneutropaenic
children in the intensive care unit, especially in cases of exten-
sive abdominal surgery (recommendation not rated).
Secondary Prophylaxis
Secondary chemoprophylaxis, as a term, is ill-deﬁned for
invasive candidiasis and may overlap with continued treat-
ment or maintenance treatment in chronic disseminated
candidiasis with an agent that has proven efﬁcacy against
Candida spp. [109]. Similar to adults, secondary chemopro-
phylaxis is not indicated in case of prior uncomplicated can-
didaemia without any sign of deep seated infection –
including situations in which the patient is exposed to a
new immunosuppressive condition such as prolonged neu-
tropaenia induced by chemotherapy, autologous or alloge-
neic HSCT (CIII).
Empirical and pre-emptive antifungal therapy
Empirical antifungal therapy is considered by many experts a
standard of care in haemato-oncological patients with pro-
longed neutropaenia (ANC <500 for ‡10 days) and refrac-
tory or new fever, despite broad-spectrum empirical
antibacterial therapy. It may provide targeted prevention in a
high-risk situation and early treatment of yet occult infec-
tions. Based on large randomized clinical trials with inclusion
and separate analysis of paediatric patients [110–113], ade-
quate paediatric PK and safety data, recommended options
in paediatric patients of all age groups include liposomal
amphotericin B (1–3 mg/kg QD) (A-I) and caspofungin (load-
ing dose 70 mg/m2/day, followed by 50 mg/m2/day. Option
TABLE 4. Treatment of invasive candidiasis in children
Recommendation and Grading Comments References
Amphotericin B deoxycholate 0.6–1 mg/kg/
day (C-I)
Lipid preparations of amphotericin B have a more
favourable toxicity proﬁle
Issues related to supply in some European countries
Clinical trials in adults [123,124]
PK studies in children [132]
Evidence for safety and efﬁcacy in children with invasive
candidiasis: Nil
Liposomal amphotericin B 3 mg/kg/day (A-I) Clinical trials in adults and children [48,127]
PK studies in children [105]
Safety in children [48]
Fluconazole
8–12 mg/kg/day (B-I)
Fungistatic antifungal activity Evidence for efﬁcacy in adults [123,139]
PK studies in children [73]
Evidence for safety and efﬁcacy in children [75]
Voriconazole (day 1: 9 mg/kg Q12h, then
8 mg/kg BID i.v.); and 9 mg/kg BID for oral
administration (max.: 350 mg BID) for the
ages of 2–14 years and the approved adult
dose for patients 15 years and older and
12–14 year olds weighing >50 kg; after last
dose of chemotherapy until neutrophil
recovery (B-I)
Fungistatic antifungal activity
Spectrum extends to Candida glabrata and Candida krusei
TDM should be considered
Evidence for efﬁcacy in adults [134]
PK studies in children: [84–88]
TDM dosing target: [89–91]
Micafungin
<40 kg 2–4 mg/kg (A-I)
Well conducted PK trials to deﬁne dosages that lead to
comparable drug exposures in children
The EMA has issued a ‘black box’ warning on the basis of
an elevated incidence of hepatic tumours in rats
receiving prolonged dosing and drug exposures higher
than typically seen in clinical contexts.
Efﬁcacy established in clinical trials in children and
adults [48,127]
PK studies in children: [96,97]
Safety/efﬁcacy in children [98]
Anidulafungin
3 mg/kg as a single loading dose followed by
1.5 mg/kg/day (B-II)
Some uncertainty about optimal paediatric regimen
because of relatively limited PK data
No data for efﬁcacy and safety in children
Evidence for efﬁcacy in adults [128]
PK studies in children [129]
Caspofungin
Loading dose 70 mg/m2/day, followed by
50 mg/m2/day. Option to increase to
70 mg/m2/day if clinically indicated,
maximum absolute dose of 70 mg/day (A-I)
Evidence for efﬁcacy in adults [124]
PK studies in children [125]
Evidence for safety in children [126]
Amphotericin B Lipid Complex (B-II) Relatively limited clinical data for efﬁcacy and safety
No PK data for children
Evidence for efﬁcacy and safety [131,140]
PK in children: nil
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to increase to 70 mg/m2/day if clinically indicated with a max-
imum dose of 70 mg/day) (A-I). Of note, incidence and
extent of nephrotoxicity of liposomal amphotericin B in chil-
dren appears to be lower than in adults, hence the higher
rating compared with adults. Fluconazole may be used if the
incidence of invasive aspergillosis is low or if a mould-speciﬁc
diagnostic algorithm is being used (B-II) [114]. Amphotericin
B deoxycholate 0.7–0.8 mg/kg/day may be reasonable if this
compound is available, and the higher toxicity is tolerable
from a clinical perspective (B-II).
Empirical therapy in adult ICU patients has been shown to
be of no beneﬁt when using a fever criterion [115], but no
data exist for nonneonatal paediatric patients. While several
studies in adult ICU patients show potential utility of scoring
systems as the basis for pre-emptive treatment of invasive
candidiasis (see for example [116–120]), no data exist in
other populations and in paediatric patients, and therefore,
no recommendations are made.
Treatment of invasive candidiasis and
candidaemia in children
General principles
Many of the general principles pertinent to the management of
invasive candidiasis in children are derived from adults, and
these are as follows: (i) antifungal therapy should be adminis-
tered as quickly as possible (extrapolated from [121,122]); (ii)
the optimal duration of therapy is 14 days after blood cultures
are sterile, provided there is no unresolved deep infection or a
severe persistent underlying immunological deﬁcit (extrapo-
lated from [123]); (iii) the appropriate choice of an anti-Can-
dida agent may be inﬂuenced by local epidemiology because of
the reduced susceptibility or resistance of some species to
certain antifungal classes/agents; (iv) clinical evaluation for deep
sites of infection, including an ophthalmological examination is
required in all cases of candidaemia; (v) consideration should
be given to removing or at least replacing intravenous cathe-
ters and/or other implanted prosthetic devices in a timely
manner; and (vi) there is no ﬁrm recommendation regarding
combination antifungal chemotherapy, but this may be consid-
ered in some situations (e.g. severe life-threatening infection,
compromised drug penetration (e.g. cases of CNS infection,
osteomyelitis, complicated urinary tract infections and compli-
cated intra-abdominal infections).
Echinocandins
The echinocandins are ﬁrst-line agents for the treatment of IC
in children. The Expert Group does not consider that there
are signiﬁcant microbiological nor pharmacological differences
between caspofungin, micafungin and anidulafungin. Differences
in recommendations reﬂect the different stages in the develop-
ment of these compounds for paediatric patients. Caspofungin
(70 mg/m2 loading dose followed by 50 mg/m2/day i.v.) can be
used for the treatment of IC (A-I). This recommendation is
based on established efﬁcacy in adults, a well-designed PK
study [124,125], documented safety [126] and the existence of
a paediatric label from the EMA. Similarly, micafungin (2–4 mg/
kg/day i.v.) can also be used (A-I); this recommendation is
based on a randomized control trial in adults and children
[48,127], extensive pharmacokinetics [96,97], safety data [98]
and the existence of a paediatric label. Anidulafungin (3 mg/kg
loading dose, followed by 1.5 mg/day) is an alternative agent
(B-II). While there is a RCT in adults [128] and some paediatric
PK data [129], the Expert Group suggests a lower level recom-
mendation for children because of uncertainty regarding the
optimal paediatric dosage and relatively limited paediatric
safety data. The Expert Group anticipates an ‘upgrading’ of ani-
dulafungin with further clinical and PK studies and future regu-
latory approval for use in paediatric patients.
Amphotericin B formulations
Liposomal amphotericin B 3 mg/kg/day is an alternative ﬁrst-
line agent (A-I). This is based on a RCT in adults and chil-
dren, concomitant pharmacokinetic studies [48,105,106,127]
and safety data in children [48]. A higher rating compared
with adults (i.e. B-I) is based on the lower incidence of toxic-
ity in children [48,106]. ABLC is an alternative agent for IC,
and there is some clinical experience in children [130,131].
Because of an absence of pharmacokinetic studies, and some
uncertainty regarding the optimal regimen for invasive candi-
diasis, the Expert Group rated this agent B-II. Amphotericin
B deoxycholate 0.6–1 mg/kg can be used for IC (C-I). This
recommendation is supported by clinical data from adults
[123,124] and concomitant PK data for children [132,133].
Amphotericin B deoxycholate is graded lower than lipid
preparations principally because of a less favourable toxicity
proﬁle. Nevertheless, the Expert Group recognizes the use
of amphotericin B deoxycholate for treatment of IC may be
appropriate if other amphotericin B formulations are not
available and also recognize a different grading compared
with adults.
Triazoles
The triazoles have been widely used for treatment of inva-
sive candidiasis in children. The use of ﬂuconazole 8–12 mg/
kg/day i.v. [B-I] is based on extensive RCT data in adults and
paediatric PK studies [73,123,124,128] and extensive safety
data [75]. The lower rating than suggested for prophylaxis
reﬂects a fungistatic mode of activity. Nevertheless, ﬂuconaz-
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ole may be a reasonable initial choice for children with
IC who are haemodynamically stable and if there is a low
institutional incidence of less susceptible or frankly resistant
Candida species. There is some uncertainty regarding the use
of ﬂuconazole for Candida glabrata infections because this
organism tends to exhibit higher MICs. Candida krusei is
intrinsically resistant to ﬂuconazole, and this agent should
not be used in this context. Voriconazole (day 1: 9 mg/kg
Q12 h, then 8 mg/kg BID i.v.); 9 mg/kg Q12 h PO (max.
350 mg Q12 h) for 2–12 years and 12–14 years with <50 kg;
adult dose for patients 12–14 years >50 kg and patients
>14 years) can be used for IC. A recommendation of B-I is
based on a RCT in adults coupled with several well-designed
PK studies in children [84–89,134]. Therapeutic drug moni-
toring should be performed. The ‘B’ rating reﬂects the fungi-
static pattern of killing that appears common to the
triazoles. Voriconazole is more potent in vitro against Candida
glabrata than ﬂuconazole and has activity against Candida kru-
sei and may be a reasonable choice for these infections.
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